Eli Lilly posts full trial data for obesity pill (LLY:NYSE) – Seeking Alpha
Eli Lilly posts full trial data for obesity pill (LLY:NYSE) Seeking Alpha Eli Lilly’s obesity pill outperforms Novo Nordisk’s oral drug in head-to-head diabetes trial CNBC Lilly’s oral GLP-1, orforglipron, demonstrated meaningful weight loss and cardiometabolic improvements in complete ATTAIN-1 results published in The New England Journal of Medicine Eli Lilly and Company Daily weight loss pill can […]
Lilly, Novo showcase new obesity drug data; Fasenra falls short in COPD
Lilly claimed success in a head-to-head trial of oral GLP-1 drugs. Elsewhere, Novo planned a new weight loss trial and an AI-focused startup raised its second ‘megaround.’
Antipsychotic-treated patients with schizophrenia see benefits from semaglutide, study claims
A multicenter collaboration of Danish researchers reports that once-weekly semaglutide for 30 weeks lowered blood sugar levels and body weight and improved physical quality of life in antipsychotic-treated adults with schizophrenia and prediabetes.
Swiss Re Says GLP-1 Drugs Could Reduce US Mortality by Up to 6.4%
Reinsurance company Swiss Re said on Wednesday that widespread use of GLP-1 drugs to treat obesity could reduce the annual rate of death by up to 6.4% in the United States… Reuters Health Information
Opinion: Serena Williams, weight loss and the perils of mixed messaging
Retired tennis star Serena Williams revealed during a recent TV interview that she is taking a GLP-1 medication to help her achieve a “healthy” weight. Read More
Lilly rounds out oral GLP-1 weight loss data, posts semaglutide-topping results in diabetes
At this year’s meeting of the European Association for the Study of Diabetes (EASD) in Vienna, Eli Lilly bolstered the case for its oral GLP-1 orforglipron, showing that its pill can both stand on its own in obesity and go toe-to-toe with a rival candidate from Novo Nordisk in diabetes.
FDA calls out Hims and other telehealth companies for GLP-1 advertising
The FDA issued warning letters to telehealth companies for making “false or misleading” claims about compounded GLP-1 obesity drugs. The letters were part of a larger group of warnings posted on Tuesday that were sent …
STAT+: Lilly’s GLP-1 pill outperforms Novo’s oral treatment in diabetes study
An investigational GLP-1 pill from Eli Lilly helped diabetes patients lower their blood sugar and weight more than an oral version of Ozempic sold by Novo Nordisk, results that support the efficacy of Lilly’s medicine as the company prepares to submit it to regulators. In a yearlong Phase 3 trial, the highest dose of Lily’s […]
Lilly’s diabetes pill beats Novo’s Rybelsus in head-to-head trial, company mulls fast-track filing
Eli Lilly said Wednesday that orforglipron beat Novo Nordisk’s oral drug Rybelsus in a head-to-head trial in diabetes patients, the latest twist in the Indianapolis drugmaker’s efforts to get its obesity pill to market. …
Obesity drugs could reduce US mortality by up to 6.4%
Swiss Re’s research was done under a scenario of GLP-1 drugs getting used at a high rate and long term, with users also changing their lifestyles. (EPA Images pic) FRANKFURT: Reinsurance company Swiss Re said on Wednesday that widespread use of GLP-1 drugs to treat obesity could reduce the annual rate of death by up […]